

**TENTATIVE PROGRAM as of June 30, 2010**

September 15 <sup>th</sup> , 2010		
From 19:00	<b>WELCOME RECEPTION</b> "Den Norske Opera"	Stian Berger Røsland, Governing Major of Oslo S.E. Brigitte Collet, French Ambassador in Norway
September 16 <sup>th</sup> , 2010		
8:00 – 9:00	Registration & Welcome Coffee	Moderator of the day : <b>Richard Gallagher</b> , founding editor of "The Scientist" magazine
9:00 – 9:15	<b>WELCOME ADDRESS</b>	<b>Pierre Montoriol</b> , President Cancer-Bio-Santé <b>Jonas Einarsson</b> , President Oslo Cancer Cluster
9:15 – 11:00	<b>ONCOLOGY 2020</b> Perspectives for the decade ahead  Keynote presentations	Moderator: <b>Richard Gallagher</b> <ul style="list-style-type: none"> <li>• Open innovation networks / personalized medicine (title tba) <b>Prof. Jonathan Knowles</b>, Inst. for Molecular Medicine Finland &amp; Ecole Polytechnique Federale de Lausanne</li> <li>• Perspectives for new drug development, <b>Prof. Jean-Pierre Armand</b>, General Director Inst. Claudius Regaud, Toulouse</li> <li>• The global cancer burden – opportunities for the next decade, <b>Doug Ulman</b>, President &amp; CEO of the Lance Armstrong Foundation</li> </ul>
11:00 – 11:20	Coffee Break	
11:20 – 12:35	<b>PARTNERING</b> Biomarkers – new companion diagnostics in oncology  Pharma Needs Case Studies	Moderator: <b>Tom Pike</b> , Credio AS, Oslo <ul style="list-style-type: none"> <li>• Cancer Genome projects and the future individualized medicine, <b>Prof. Olli Kallioniemi</b>, Director, Institute for Molecular Medicine Finland</li> <li>• Case study: Companion Diagnostics in Oncology, <b>Evelyn McKeegan</b>, GPRD Cancer Discovery / Cancer Biomarkers, Abbott</li> <li>• Case Study: Title to be announced, <b>Ginette Serrero</b>, CEO, A&amp;G Pharmaceutical, Inc.</li> </ul>
12:35 – 13:50	Networking Lunch	
13:50 – 14:10	<b>PHARMA NEEDS</b>	MSD Presentation (Title to be announced) <b>Dr. Jeroen Tonnaer</b> , Executive Group Leader Worldwide Licensing MSD
14:10 – 15:30	<b>CLINICAL TRIALS</b> Oncology-focused networks accelerating R&D  Presentations Roundtable	Moderator: <b>Prof. Jean-Pierre Armand</b> , General Director Institute Claudius Regaud, Toulouse <ul style="list-style-type: none"> <li>• A European Phase I Clinical trial network to shorten development timelines, <b>Prof. Jean-Pierre Armand</b></li> <li>• A Nordic node and its contribution to the European clinical trial network, <b>Prof. Steinar Aamdal</b>, Oslo University Hospital</li> <li>• OncoNET: a new collaborative model for early clinical development; <b>Gunnar Sæter</b>, Regional Director Medical Affairs Oncology, MSD</li> <li>• PANEL: Speakers, <b>Prof. Gerd Mikus</b>; Deputy Medical Director of the Dept. Clinical Research Unit, University Hospital Heidelberg, <i>additional participants to be determined</i></li> </ul>
15:30 – 15:45	Coffee Break	
15:45 – 17:15	<b>INVESTMENTS</b> The anatomy of VC financing and big company partnering	Moderator: <b>Carl Chr. Gilhuus-Moe</b> , Senior Partner NeoMed Management <ul style="list-style-type: none"> <li>• Financing of Emerging Life Science Companies: A Venture Capitalist View <b>Erik Amble</b>, Managing Partner, NeoMed Management</li> <li>• Big Company M&amp;A and Strategic Alliances: Opportunities and Challenges <b>Medtronic Inc.</b> (Speaker to be announced)</li> <li>• Strategy for early stage investments in the US and in Europe <b>Kermit Nash, Esqr.</b>, <b>Gray Plant Mooty</b></li> </ul>
From 19:00	<b>NETWORKING EVENING</b>	

ONE-TO-ONE MEETINGS

ONE-TO-ONE MEETINGS

ONE-TO-ONE MEETINGS

ONE-TO-ONE MEETINGS

8:00 – 9:00	Registration & Welcome Coffee	Moderator of the day: <i>to be announced</i>	
9:00 – 10:15	<p><b>ONCOLOGY 2020</b>  <b>Global Networks to speed-up innovation</b></p> <p><b>Keynote Presentation Roundtable</b></p>	<p>Moderator &amp; Keynote Speaker: <b>Prof. Neil L. Spector Director, Duke Translational Oncology Research and Co-Director Experimental Therapeutics Program</b></p> <ul style="list-style-type: none"> <li>Translating scientific concepts into innovative treatments – lessons learned and outlook for the next decade; <b>Prof. Neil L. Spector</b></li> </ul> <p>ROUNDTABLE:</p> <ul style="list-style-type: none"> <li><b>Dr. William Greenlee, CEO, The Hamner Institutes for Health Sciences</b></li> <li><b>Prof. Jun Ren; Executive Director, National Clinical Trial Centre Peking University School of Oncology/Beijing Cancer Hospital and Director Duke Peking University Medicine Collaborative Program</b></li> <li><b>Representative of the Beijing Pharma and Biotech Centre (to be confirmed)</b></li> <li><b>Prof. Ada Kruisbeek, Scientific Director TTO VU University &amp; Medical Center Amsterdam (invited)</b></li> <li><b>Jean-Pierre Saintouil, CEO Cancer-Bio-Santé</b></li> <li><b>Bjarte Reve, CEO Oslo Cancer Cluster</b></li> </ul>	ONE-TO-ONE MEETINGS
10:15 – 10:30	Coffee Break		
10:30 – 12:40	<p><b>PARTNERING</b>  <b>Emerging strategies to tap innovation</b></p> <p><b>Pharma &amp; Biotech Needs Case Studies</b></p>	<p>Moderator: <i>to be announced</i></p> <ul style="list-style-type: none"> <li><b>Amgen Presentation (Title to be announced), Dr. Thomas Lillie, International Development Executive Medical Director Amgen</b></li> <li><b>Sanofi-Aventis presentation (details to be confirmed)</b></li> <li><b>Case Study: The Astra Zeneca and Cancer Research Technology Alliance, Dr Chris Sheldon, Business Development Manager, Astra Zeneca</b></li> <li><b>Case Study: Pierre-Fabre partnerships (title to be announced), Dr. Laurent Nguyen Cong Duc; VP Corporate Licensing &amp; Acquisitions, Pierre Fabre Group</b></li> </ul>	ONE-TO-ONE MEETINGS
12:40 – 13:30	Networking Lunch		
13:30 – 15:10	<p><b>PARTNERING</b>  <b>Positioning as key</b></p> <p><b>Pharma Needs Case Studies</b></p>	<p>Moderator: <b>Kjetil Hestdal, President &amp; CEO, Photocure ASA</b></p> <ul style="list-style-type: none"> <li><b>Case study: The Algeta-Bayer collaboration; Karen Denton, Director Alliance Management Bayer Health Care Pharmaceuticals and Roger Harrison, Chief Business Officer Algeta ASA</b></li> <li><b>Case study: The Transgene – Novartis collaboration; Anne Altmeyer, Executive Director, Business Development and Licensing Novartis and Jean-Yves Bonnefoy, Vice President R&amp;D Transgene</b></li> <li><b>Case study: Clavis Pharma and Clovis Oncology: The building up of a Trans Atlantic Alliance, Jan Alfheim, CBO Clavis Pharma ASA</b></li> </ul>	ONE-TO-ONE MEETINGS
15:10 – 15:30	<b>CLOSING SESSION</b>		
From 15:30	<b>Closing Cocktail</b>		

